BioXcel Therapeutics Inc Q1 2019 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Do Kim - BMO Capital Markets Equity Research - Analyst : Congrats on the progress. First on 501, maybe this is a pretty simplistic question. But when we see the bioavailability data, how should we be interpreting the results? Is it as straightforward as just assuming that a similar PK will give you the same responses as the intravenous proof-of-concept studies? Or are there other factors we should be considering?

Question: Do Kim - BMO Capital Markets Equity Research - Analyst : Great. And if Vince is on -- I had a question on the AACR presentation in combo with OX40. Maybe if you could go over the rationale of combining OX40 agonist over targeting other co-stimulatory molecules. Is there anything specific about OX40?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Limited, Research Division - Analyst : I have 2. The first on 501. I know you have a lot of indications going on, on that film. But I was especially intrigued by language in your press release on the same formulation that said it might be flexible for combination therapies. So what are some of the options that might be on the table in terms of products that could be combined in the film and what types of indications could be tolerated there? And then I have a follow-up on 701.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Limited, Research Division - Analyst : Got it. And then on 701, could you remind us of some of the specific timelines of when we should be seeing data readouts from trials in tNEPC and in pancreatic cancer? Or asked another way, I guess what should we be expecting on that program in the second half of this year in terms of data readouts?